NGL Fine-Chem Ltd
Company Profile
Business description
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
Contact
301, E Square, Subhash Road
Vile Parle (East)
MumbaiMH400057
INDT: +91 2240842222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
523
Stocks News & Analysis
stocks
Finding yield on the ASX
stocks
ExxonMobil earnings: Continued execution, on track for 2030 targets
stocks
Disney earnings: No big surprises in solid results
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,181.40 | 25.20 | 0.28% |
| CAC 40 | 8,181.17 | 54.64 | 0.67% |
| DAX 40 | 24,797.52 | 258.71 | 1.05% |
| Dow JONES (US) | 49,407.66 | 515.19 | 1.05% |
| FTSE 100 | 10,341.56 | 118.02 | 1.15% |
| HKSE | 26,775.57 | 611.54 | -2.23% |
| NASDAQ | 23,592.11 | 130.29 | 0.56% |
| Nikkei 225 | 53,898.91 | 1,243.73 | 2.36% |
| NZX 50 Index | 13,460.39 | 47.95 | 0.36% |
| S&P 500 | 6,976.44 | 37.41 | 0.54% |
| S&P/ASX 200 | 8,890.20 | 23.90 | 0.27% |
| SSE Composite Index | 4,015.75 | 102.20 | -2.48% |